Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 1, 2012, Pages 92-104

  Sebastiani, G ^a   Halfon, P ^b   Castera, L ^c   Mangia, A ^d   Di Marco, V ^e   Pirisi, M ^f   Voiculescu, M ^g   Bourliere, M ^h   Alberti, A ^a,i  

^a VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^b Hospital Ambroise Pare   (France)

^c BEAUJON HOSPITAL   (France)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

^f UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^g FUNDENI CLINICAL INSTITUTE   (Romania)

^h HÔPITAL SAINT JOSEPH   (France)

ⁱ UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN;

ADULT; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL TO PLATELET RATIO; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FIBROPACA ALGORITHM; FIBROTEST; FORNS' INDEX; HEPATITIS C; HUMAN; INTERMETHOD COMPARISON; LEROY ALGORITHM; LIVER BIOPSY; LIVER EXAMINATION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INVASIVE MEASUREMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEQUENTIAL ALGORITHM FOR FIBROSIS EVALUATION; THROMBOCYTE COUNT;

ALGORITHMS; ALPHA-MACROGLOBULINS; APOLIPOPROTEIN A-I; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BIOLOGICAL MARKERS; BIOPSY; CHOLESTEROL; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HAPTOGLOBINS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET COUNT; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RNA, VIRAL; SENSITIVITY AND SPECIFICITY;

EID: 83555174927     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04897.x     Document Type: Article

References (52)

1. Seeff LB,. Natural history of chronic hepatitis C. Hepatology 2002; 36 (5 Suppl 1): S35-46. (Pubitemid 35253462)
2. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
3. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD,. Liver biopsy. Hepatology 2009; 49: 1017-44.
4. Bedossa P, Dargere D, Paradis V,. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57. (Pubitemid 37466971)
5. Colloredo G, Guido M, Sonzogni A, Leandro G,. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39: 239-44. (Pubitemid 36920560)
6. Guido M, Rugge M,. Liver biopsy sampling in chronic viral hepatitis. Semin Liver Dis 2004; 24: 89-97. (Pubitemid 38496051)
7. Rousselet MC, Michalak S, Dupre F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41: 257-64. (Pubitemid 40165369)
8. Wong JB, Koff RS,. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 2000; 133: 665-75.
9. Bonny C, Rayssiguier R, Ughetto S, et al. [Medical practices and expectations of general practitioners in relation to hepatitis C virus infection in the Auvergne region]. Gastroenterol Clin Biol 2003; 27: 1021-5. (Pubitemid 37516827)
10. Almasio PL, Niero M, Angioli D, et al. Experts' opinions on the role of liver biopsy in HCV infection: a Delphi survey by the Italian Association of Hospital Gastroenterologists (A.I.G.O.). J Hepatol 2005; 43: 381-7. (Pubitemid 41111417)
11. Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A,. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002; 137: 961-4. (Pubitemid 35440242)
12. Manning DS, Afdhal NH,. Diagnosis and quantitation of fibrosis. Gastroenterology 2008; 134: 1670-81. (Pubitemid 351615414)
13. Pinzani M, Vizzutti F, Arena U, Marra F,. Technology insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 95-106. (Pubitemid 351234279)
14. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26. (Pubitemid 36919874)
15. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36 (4 Pt 1): 986-92.
16. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T,. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75. (Pubitemid 32322537)
17. Sebastiani G, Alberti A,. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006; 12: 3682-94. (Pubitemid 43950946)
18. Poynard T, Morra R, Halfon P, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC gastroenterology 2007; 7: 40.
19. Shaheen AA, Wan AF, Myers RP,. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007; 102: 2589-600. (Pubitemid 47631778)
20. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53: 726-36.
21. Sebastiani G, Vario A, Guido M, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006; 44: 686-93.
22. Bourliere M, Penaranda G, Renou C, et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat 2006; 13: 659-70. (Pubitemid 44401194)
23. Leroy V, Hilleret MN, Sturm N, et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46: 775-82. (Pubitemid 46529041)
24. Smith JO, Sterling RK,. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther 2009; 30: 557-76.
25. Shiha G, Sarin SK, Ibrahim AE, et al. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hep Intl 2009; 3: 323-33.
26. Sebastiani G, Halfon P, Castera L, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1821-7.
27. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20 (1 Pt 1): 15-20.
28. Zeng MD, Lu LG, Mao YM, et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005; 42: 1437-45.
29. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-6. (Pubitemid 47171918)
30. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-73. (Pubitemid 41368177)
31. DeLong ER, DeLong DM, Clarke-Pearson DL,. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45.
32. Hanley JA, McNeil BJ,. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36. (Pubitemid 12142173)
33. Poynard T, Halfon P, Castera L, et al. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem 2007; 53: 1615-22. (Pubitemid 47340057)
34. Thabut D, Simon M, Myers RP, et al. Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology 2003; 37: 1220-1, author reply 1221.
35. Wachtel MS, Zhang Y, Kaye KE, Chiriva-Internati M, Frezza EE,. Increased age, male gender, and cirrhosis, but not steatosis or a positive viral serology, negatively impact the life expectancy of patients who undergo liver biopsy. Dig Dis Sci 2007; 52: 2276-81. (Pubitemid 47246524)
36. Floreani A,. Liver diseases in the elderly: an update. Dig Dis 2007; 25: 138-43. (Pubitemid 46663780)
37. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3: 8.
38. Schuppan D, Afdhal NH,. Liver cirrhosis. Lancet 2008; 371: 838-51. (Pubitemid 351323895)
39. Halfon P, Munteanu M, Poynard T,. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol 2008; 32 (6 Suppl 1): 22-39.
40. Thabut D, Imbert-Bismut F, Cazals-Hatem D, et al. Relationship between the Fibrotest and portal hypertension in patients with liver disease. Aliment Pharmacol Ther 2007; 26: 359-68. (Pubitemid 47063142)
41. Fontana RJ, Dienstag JL, Bonkovsky HL, et al. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010; 59: 1401-9.
42. Vergniol J, Foucher J, Terrebonne E, et al. Non-invasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970-9, 1979.e1-3.
43. Lok AS, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005; 42: 282-92. (Pubitemid 41061080)
44. Guido M, Alberti A, Bellati G, et al. Fibrotest vs. liver biopsy: a multicenter, independent evaluation of performance. Hepatology 2007; 46: [abstract].
45. Shaheen AA, Myers RP,. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46: 912-21. (Pubitemid 47436137)
46. Castera L, Sebastiani G, Le Bail B, de Ledinghen V, Couzigou P, Alberti A,. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010; 52: 191-8.
47. Bourliere M, Penaranda G, Ouzan D, et al. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients. Aliment Pharmacol Ther 2008; 28: 458-67. (Pubitemid 352033276)
48. Boursier J, Cales P,. Combination of fibrosis tests: sequential or synchronous? Hepatology 2009; 50: 656-7, author reply 657.
49. Cales P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42: 1373-81. (Pubitemid 43260040)
50. Halfon P, Bacq Y, De Muret A, et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46: 395-402. (Pubitemid 46201720)
51. Poynard T, Halfon P, Castera L, et al. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther 2007; 25: 733-9.
52. Halfon P, Bourliere M, Deydier R, et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 2006; 101: 547-55. (Pubitemid 43340931)